Meadowhawk Biolabs

Meadowhawk Biolabs is a specialized preclinical CRO founded in 2016, focusing on accelerating early-stage drug development for biotech and pharma clients. It differentiates itself by offering a fully integrated, fit-for-purpose service model that combines in vivo, LCMS, and molecular assays under one roof, operating within key life science hubs like Boston and San Francisco. The company targets the high-volume, fast-turnaround study niche, providing peer-to-peer scientist support and streamlined workflows to reduce timelines without compromising data integrity. Its expertise spans novel modalities beyond traditional small molecules, positioning it as a partner for innovative drug discovery programs.

Integrated 'Research Grade Assays®' platform combining in vivo pharmacology, LCMS bioanalysis, and molecular/immunoanalysis into a fit-for-purpose, high-velocity workflow for early-stage drug discovery.

Meadowhawk competes in a fragmented preclinical CRO market against large, full-service players (e.g., Charles River, LabCorp) and many small, specialized labs. Its differentiation lies in its integrated, end-to-end service for early-stage work, a science-first collaborative model, and a focus on speed and flexibility for novel modalities, avoiding the regulatory overhead and potential inflexibility of larger CROs.